Evidence map›Paper›PMID 40486848›Full record

ArticleActa pharmaceutica Sinica. B2025

Design, molecular characterization and therapeutic investigation of a novel CCR8 peptide antagonist that attenuates acute liver injury by inhibiting infiltration and activation of macrophages.

Eline Geervliet, Sahil Arora, Dagmara Donohue, Carlos Antonio de Albuquerque Pinheiro, Leon W M M Terstappen, Richard Schasfoort, Julieta Paez, Raj Kumar, Ruchi Bansal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eline GeervlietPersonalized Diagnostics and Therapeutics, Department of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, the Netherlands.
Sahil AroraDepartment of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, India.
Dagmara DonohuePersonalized Diagnostics and Therapeutics, Department of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, the Netherlands.
Carlos Antonio de Albuquerque PinheiroDevelopmental BioEngineering, Department of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, the Netherlands.
Leon W M M TerstappenPersonalized Diagnostics and Therapeutics, Department of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, the Netherlands.
Richard SchasfoortPersonalized Diagnostics and Therapeutics, Department of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, the Netherlands.
Julieta PaezDevelopmental BioEngineering, Department of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, the Netherlands.
Raj KumarDepartment of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, India.
Ruchi BansalPersonalized Diagnostics and Therapeutics, Department of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During liver injury, intrahepatic macrophage compartment is augmented by circulating monocytes that infiltrate the liver driven by C-C motif chemokine ligand/C-C motif chemokine receptor (CCL/CCR) axis including CCL1‒CCR8 axis, thereby contributing to liver inflammation. Numerous small molecular receptor antagonists, including R243, have been developed for targeting CCR8; however, these agents face challenges in clinical translation, potentially attributed to their poor pharmacokinetic profiles, lack of target specificity, and potential adverse effects. In this study, we designed four CCR8 antagonizing peptides (AP8i-AP8iv) and performed molecular characterization

Indexed as

CCL1‒CCR8 axisCCR8 antagonizing peptideIn silico molecular dockingIntrahepatic monocyte infiltration and differentiationIn vitro chemotaxisIn vivo acute liver injuryLiver inflammation

Identifiers

PMID40486848
PMCPMC12137978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.